[go: up one dir, main page]

ECSP13012859A - Anticuerpos del cea - Google Patents

Anticuerpos del cea

Info

Publication number
ECSP13012859A
ECSP13012859A EC2013012859A ECSP13012859A ECSP13012859A EC SP13012859 A ECSP13012859 A EC SP13012859A EC 2013012859 A EC2013012859 A EC 2013012859A EC SP13012859 A ECSP13012859 A EC SP13012859A EC SP13012859 A ECSP13012859 A EC SP13012859A
Authority
EC
Ecuador
Prior art keywords
cea antibodies
abms
cea
bind
membrane
Prior art date
Application number
EC2013012859A
Other languages
English (en)
Inventor
Ekkehard Moessner
Pablo Umana
Ralf Hosse
Thomas Hofer
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of ECSP13012859A publication Critical patent/ECSP13012859A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención proporciona moléculas de unión a antígeno (ABMs) que se unen a CEA unido a membrana, incluyendo ABMS con propiedades terapéuticas mejoradas, y métodos de utilización de las mismas.
EC2013012859A 2011-03-02 2013-08-30 Anticuerpos del cea ECSP13012859A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11156665 2011-03-02

Publications (1)

Publication Number Publication Date
ECSP13012859A true ECSP13012859A (es) 2013-10-31

Family

ID=45811481

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2013012859A ECSP13012859A (es) 2011-03-02 2013-08-30 Anticuerpos del cea

Country Status (35)

Country Link
US (7) US8642742B2 (es)
EP (2) EP2681244B1 (es)
JP (1) JP6046642B2 (es)
KR (1) KR101981342B1 (es)
CN (1) CN103403029B (es)
AR (1) AR085591A1 (es)
AU (1) AU2012222463B9 (es)
BR (1) BR112013021460B1 (es)
CA (1) CA2827722C (es)
CL (1) CL2013002203A1 (es)
CO (1) CO6781491A2 (es)
CR (1) CR20130359A (es)
DK (1) DK2681244T3 (es)
EA (1) EA029300B1 (es)
EC (1) ECSP13012859A (es)
ES (1) ES2657856T3 (es)
HR (1) HRP20180147T1 (es)
HU (1) HUE036229T2 (es)
IL (1) IL227482B (es)
LT (1) LT2681244T (es)
MA (1) MA34927B1 (es)
MX (1) MX347590B (es)
MY (1) MY164647A (es)
NO (1) NO2681244T3 (es)
PE (1) PE20141017A1 (es)
PH (1) PH12013501508B1 (es)
PL (1) PL2681244T3 (es)
PT (1) PT2681244T (es)
RS (1) RS56793B1 (es)
SG (1) SG192972A1 (es)
SI (1) SI2681244T1 (es)
TW (1) TWI553016B (es)
UA (1) UA115030C2 (es)
WO (1) WO2012117002A1 (es)
ZA (1) ZA201305323B (es)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339608B (es) * 2009-08-31 2016-05-31 Roche Glycart Ag Anticuerpos del antigeno carcinoembrionario (cea).
PL3489255T3 (pl) 2011-02-10 2021-11-22 Roche Glycart Ag Zmutowane polipeptydy interleukiny-2
MX347590B (es) * 2011-03-02 2017-05-03 Roche Glycart Ag Anticuerpos del cea.
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
PE20190658A1 (es) 2012-02-24 2019-05-08 Abbvie Stemcentrx Llc Moduladores y metodos de empleo novedosos
PE20151180A1 (es) 2012-11-20 2015-08-12 Sanofi Sa Anticuerpos anti-ceacam5 y usos de estos
RU2693078C2 (ru) 2012-12-03 2019-07-01 Новиммун С.А. Анти-cd47 антитела и способы их применения
RU2019109456A (ru) 2013-02-22 2019-04-10 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи Новые конъюгаты антител и их применения
JP2014161283A (ja) * 2013-02-26 2014-09-08 Shizuoka Prefecture Ｃｅａｃａｍ５遺伝子のスプライシングバリアント
CA2896359A1 (en) * 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
NZ708182A (en) 2013-02-26 2019-08-30 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
RU2016111131A (ru) 2013-08-28 2017-10-03 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи Способы конъюгации сайт-специфических антител и композиции
WO2015031541A1 (en) 2013-08-28 2015-03-05 Stem Centrx, Inc. Novel sez6 modulators and methods of use
US10053511B2 (en) 2013-11-06 2018-08-21 Abbvie Stemcentrx Llc Anti-claudin antibodies and methods of use
US9753036B2 (en) 2014-04-29 2017-09-05 Edp Biotech Corporation Methods and compositions for screening and detecting biomarkers
AR100271A1 (es) * 2014-05-19 2016-09-21 Lilly Co Eli Compuestos de vegfr2 / ang2
ES2979976T3 (es) 2014-08-04 2024-09-27 Hoffmann La Roche Moléculas de unión a antígeno activadoras de linfocitos T biespecíficas
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法
AU2016329111A1 (en) 2015-10-02 2018-02-08 F. Hoffmann-La Roche Ag Bispecific anti-CEAXCD3 T cell activating antigen binding molecules
CN106065032B (zh) * 2015-11-30 2019-07-09 成都金昆生物科技有限公司 一新型蛋白结合片段
EP4026848A1 (en) 2015-12-09 2022-07-13 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody for reducing the cytokine release syndrome
EP3178848A1 (en) * 2015-12-09 2017-06-14 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
RU2652955C1 (ru) * 2015-12-24 2018-05-03 Федеральное государственное бюджетное учреждение "Российский научный центр рентгенорадиологии" Министерства здравоохранения российской федерации (ФГБУ "РНЦРР" Минздрава России) Мономолекулярный химерный т-клеточный рецептор к раково-эмбриональному антигену
CA3006529A1 (en) 2016-01-08 2017-07-13 F. Hoffmann-La Roche Ag Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
CA3021098A1 (en) 2016-04-21 2017-10-26 Abbvie Stemcentrx Llc Novel anti-bmpr1b antibodies and methods of use
WO2018092885A1 (ja) 2016-11-18 2018-05-24 アステラス製薬株式会社 新規な抗ヒトＭＵＣ１抗体Ｆａｂフラグメント
KR20190136076A (ko) 2017-04-13 2019-12-09 에프. 호프만-라 로슈 아게 암 치료 방법에 사용하기 위한 인터루킨-2 면역접합체, cd40 작용제 및 임의적인 pd-1 축 결합 길항제
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
CN108219004A (zh) * 2018-02-08 2018-06-29 吉林省拓华生物科技有限公司 双特异嵌合抗原受体修饰的t细胞、其制备方法及用途
EP3762406A2 (en) 2018-03-09 2021-01-13 Askgene Pharma, Inc. Cytokine prodrugs
CA3100317A1 (en) 2018-05-17 2019-11-21 Astellas Pharma Inc. Complex having anti-human muc1 antibody fab fragment, peptide linker and/or ligand
US11555071B2 (en) 2018-06-03 2023-01-17 Lamkap Bio Beta Ltd. Bispecific antibodies against CEACAM5 and CD47
WO2020023702A1 (en) 2018-07-25 2020-01-30 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
WO2020075746A1 (ja) 2018-10-10 2020-04-16 アステラス製薬株式会社 標識部－抗ヒト抗体Ｆａｂフラグメント複合体を含む医薬組成物
CN113646332B (zh) * 2019-03-15 2024-08-23 公益财团法人癌研究会 抗平足蛋白抗体
EP3983432A1 (en) 2019-06-12 2022-04-20 Askgene Pharma, Inc. Novel il-15 prodrugs and methods of use thereof
JP2022537158A (ja) 2019-06-13 2022-08-24 ボルト バイオセラピューティクス、インコーポレーテッド アミノベンズアゼピン化合物、イムノコンジュゲート、及びそれらの使用
EP3992211A4 (en) 2019-06-26 2023-01-04 Jiangsu Hengrui Medicine Co., Ltd. ANTI-CEA ANTIBODIES AND ITS USE
AR119382A1 (es) 2019-07-12 2021-12-15 Hoffmann La Roche Anticuerpos de pre-direccionamiento y métodos de uso
WO2021046112A1 (en) 2019-09-03 2021-03-11 Bolt Biotherapeutics, Inc. Aminoquinoline compounds, immunoconjugates, and uses thereof
WO2021053587A1 (en) 2019-09-18 2021-03-25 Klaus Strein Bispecific antibodies against ceacam5 and cd3
AU2020353235A1 (en) 2019-09-28 2022-03-31 AskGene Pharma, Inc. Cytokine prodrugs and dual-prodrugs
US20220347310A1 (en) 2019-09-30 2022-11-03 Bolt Biotherapeutics, Inc. Amide-linked, aminobenzazepine immunoconjugates, and uses thereof
BR112022007719A2 (pt) 2019-10-25 2022-07-12 Bolt Biotherapeutics Inc Imunoconjugados, composto ligante, composição farmacêutica, método para tratar câncer, uso de um imunoconjugado e método de preparação de um imunoconjugado
EP3831849A1 (en) 2019-12-02 2021-06-09 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
WO2021226440A1 (en) 2020-05-08 2021-11-11 Bolt Biotherapeutics, Inc. Elastase-substrate, peptide linker immunoconjugates, and uses thereof
KR20230037578A (ko) 2020-07-10 2023-03-16 에프. 호프만-라 로슈 아게 암 세포에 결합하고 방사성 핵종을 상기 세포로 표적화하는 항체
AU2021326516A1 (en) 2020-08-13 2023-04-13 Bolt Biotherapeutics, Inc. Pyrazoloazepine immunoconjugates, and uses thereof
JP7657292B2 (ja) 2020-08-20 2025-04-04 エー２ バイオセラピューティクス， インコーポレイテッド Ｃｅａｃａｍ陽性がんを治療するための組成物及び方法
EP4100028A4 (en) 2020-08-20 2023-07-26 A2 Biotherapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF MESOTHELIN-POSITIVE CARCINOMAS
US20220195066A1 (en) 2020-12-11 2022-06-23 Bolt Biotherapeutics, Inc. Anti-cea immunoconjugates, and uses thereof
EP4259210A2 (en) 2020-12-11 2023-10-18 Bolt Biotherapeutics, Inc. Anti-cea immunoconjugates, and uses thereof
WO2022133042A1 (en) * 2020-12-18 2022-06-23 Bioardis, Llc Cea5 binding molecules and uses thereof
AU2021400227A1 (en) 2020-12-18 2023-04-27 Lamkap Bio Beta Ltd Bispecific antibodies against ceacam5 and cd47
PE20240690A1 (es) 2021-01-12 2024-04-10 Hoffmann La Roche Anticuerpos split que se unen a celulas cancerosas y dirigen radionuclidos a dichas celulas
EP4277668A1 (en) 2021-01-13 2023-11-22 F. Hoffmann-La Roche AG Combination therapy
JP2024511277A (ja) 2021-02-19 2024-03-13 メビオン・メディカル・システムズ・インコーポレーテッド 粒子線治療システムのためのガントリー
CN112557662B (zh) * 2021-02-22 2021-07-06 和卓生物科技（上海）有限公司 一种结直肠癌检测试剂盒
CA3212926A1 (en) 2021-03-26 2022-09-29 Gary Brandt 2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof
EP4313161A1 (en) 2021-03-26 2024-02-07 Bolt Biotherapeutics, Inc. 2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof
TW202243689A (zh) 2021-04-30 2022-11-16 瑞士商赫孚孟拉羅股份公司 抗ｃｄ２０／抗ｃｄ３雙特異性抗體及抗ｃｄ７８ｂ抗體藥物結合物的組合治療之給藥
CN115819596A (zh) * 2021-09-17 2023-03-21 优迈生物科技(连云港)有限公司 一种靶向人ceacam5/6的抗体、制备方法和应用
AU2023232992A1 (en) 2022-03-07 2024-08-15 Novimmune Sa Cd28 bispecific antibodies for targeted t cell activation
US12122850B2 (en) 2022-03-14 2024-10-22 LamKap Bio gamma AG Bispecific GPC3xCD28 and GPC3xCD3 antibodies and their combination for targeted killing of GPC3 positive malignant cells
MX2024011519A (es) 2022-03-23 2024-09-24 Synaffix Bv Conjugados de anticuerpos para el direccionamiento contra tumores que expresan el antigeno carcinoembrionario.
WO2024110905A1 (en) 2022-11-24 2024-05-30 Beigene, Ltd. Anti-cea antibody drug conjugates and methods of use
TW202528350A (zh) * 2023-11-10 2025-07-16 大陸商信達生物製藥（蘇州）有限公司 抗ｄｒ５和ｃｅａｃａｍ５的雙特異性抗體及其用途
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2026019161A1 (ko) * 2024-07-19 2026-01-22 주식회사 다안바이오테라퓨틱스 신규한 항-ceacam5 항체 및 그의 치료제로서의 용도

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
GB9317423D0 (en) * 1993-08-21 1993-10-06 Imp Cancer Res Tech Monoclonal antibodies
GB9324807D0 (en) 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
US5874540A (en) * 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
AU752494B2 (en) * 1998-02-25 2002-09-19 Dow Chemical Company, The High affinity humanized ANTI-CEA monoclonal antibodies
US6602684B1 (en) 1998-04-20 2003-08-05 Glycart Biotechnology Ag Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2270150B2 (en) 1999-04-09 2019-08-07 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
AU2001288226B2 (en) 2000-07-31 2007-07-26 Synthon Biopharmaceuticals B.V. Expression of biologically active polypeptides in duckweed
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
MXPA04001072A (es) 2001-08-03 2005-02-17 Glycart Biotechnology Ag Variantes de glicosilacion de anticuerpos que tienen citotoxicidad celulares dependiente de anticuerpos incrementada.
ATE430580T1 (de) 2001-10-25 2009-05-15 Genentech Inc Glycoprotein-zusammensetzungen
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
EP1467615B2 (en) 2001-12-27 2017-03-22 GlycoFi, Inc. Methods to engineer mammalian-type carbohydrate structures
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
EP2319935B1 (en) 2002-03-19 2016-04-27 Stichting Dienst Landbouwkundig Onderzoek GnTIII (UDP-N-acetylglucosamine:Beta -D mannoside Beta (1,4)-N-acetylglucosaminyltransferase III) expression in plants.
CA2481925A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for patients having human fc.gamma.riiia
EP1500698B1 (en) 2002-04-09 2011-03-30 Kyowa Hakko Kirin Co., Ltd. Cell with depression or deletion of the activity of protein participating in gdp-fucose transport
CA2481837A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
CN1930288B (zh) 2002-04-09 2012-08-08 协和发酵麒麟株式会社 基因组被修饰的细胞
WO2003085119A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcϜ RECEPTOR IIIa
US7232888B2 (en) 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens
ATE472604T1 (de) 2002-09-12 2010-07-15 Greenovation Biotech Gmbh Verfahren zur herstellung von proteinen
AU2003294912B2 (en) 2002-12-20 2009-06-04 Greenovation Biotech Gmbh Production of heterologous glycosylated proteins in bryophyte cells
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
NZ591970A (en) 2003-01-22 2012-11-30 Roche Glycart Ag Fusion constructs and use of same to produce antibodies with increased fc receptor binding affinity and effector function
US20090005257A1 (en) 2003-05-14 2009-01-01 Jespers Laurent S Process for Recovering Polypeptides that Unfold Reversibly from a Polypeptide Repertoire
CN103172731A (zh) * 2004-07-15 2013-06-26 赞科股份有限公司 优化的Fc变体
WO2006085518A1 (ja) * 2005-02-08 2006-08-17 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute 抗体の改良方法
MX339608B (es) * 2009-08-31 2016-05-31 Roche Glycart Ag Anticuerpos del antigeno carcinoembrionario (cea).
CA2773515C (en) * 2009-09-29 2015-04-28 Roche Glycart Ag Bispecific death receptor agonistic antibodies
PL3489255T3 (pl) * 2011-02-10 2021-11-22 Roche Glycart Ag Zmutowane polipeptydy interleukiny-2
MX347590B (es) * 2011-03-02 2017-05-03 Roche Glycart Ag Anticuerpos del cea.
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
NZ702241A (en) * 2012-08-07 2018-04-27 Roche Glycart Ag Composition comprising two antibodies engineered to have reduced and increased effector function
CA2896359A1 (en) * 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
NZ708182A (en) * 2013-02-26 2019-08-30 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
CA2951604A1 (en) * 2014-08-29 2016-03-03 Pablo Umana Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1

Also Published As

Publication number Publication date
CR20130359A (es) 2013-11-11
US20140212408A1 (en) 2014-07-31
PT2681244T (pt) 2018-01-24
MX2013009664A (es) 2013-10-30
AU2012222463B2 (en) 2017-05-04
MY164647A (en) 2018-01-30
ES2657856T3 (es) 2018-03-07
HRP20180147T1 (hr) 2018-02-23
SI2681244T1 (en) 2018-03-30
MA34927B1 (fr) 2014-02-01
TW201249873A (en) 2012-12-16
BR112013021460B1 (pt) 2022-12-20
US20190185583A1 (en) 2019-06-20
EA029300B1 (ru) 2018-03-30
CA2827722A1 (en) 2012-09-07
CO6781491A2 (es) 2013-10-31
PL2681244T3 (pl) 2018-04-30
EP2681244A1 (en) 2014-01-08
ZA201305323B (en) 2016-02-24
HK1187056A1 (zh) 2014-03-28
DK2681244T3 (da) 2018-01-29
AU2012222463A8 (en) 2013-09-05
WO2012117002A1 (en) 2012-09-07
IL227482A0 (en) 2013-09-30
EP3333193A1 (en) 2018-06-13
US8642742B2 (en) 2014-02-04
CN103403029A (zh) 2013-11-20
PH12013501508A1 (en) 2013-09-16
US20220002441A1 (en) 2022-01-06
US20180079827A1 (en) 2018-03-22
KR101981342B1 (ko) 2019-05-22
NO2681244T3 (es) 2018-04-28
US20120251529A1 (en) 2012-10-04
US20230365711A1 (en) 2023-11-16
JP2014509200A (ja) 2014-04-17
HUE036229T2 (hu) 2018-06-28
JP6046642B2 (ja) 2016-12-21
KR20140021588A (ko) 2014-02-20
LT2681244T (lt) 2018-02-12
CN103403029B (zh) 2015-11-25
BR112013021460A2 (pt) 2016-10-25
TWI553016B (zh) 2016-10-11
RS56793B1 (sr) 2018-04-30
EA201300978A1 (ru) 2014-02-28
SG192972A1 (en) 2013-09-30
EP2681244B1 (en) 2017-11-29
AU2012222463B9 (en) 2017-05-25
PH12013501508B1 (en) 2018-12-19
UA115030C2 (uk) 2017-09-11
NZ614125A (en) 2015-07-31
AU2012222463A1 (en) 2013-07-25
IL227482B (en) 2019-10-31
US9206260B2 (en) 2015-12-08
CA2827722C (en) 2020-05-12
CL2013002203A1 (es) 2013-12-06
US20160229923A1 (en) 2016-08-11
AR085591A1 (es) 2013-10-16
MX347590B (es) 2017-05-03
PE20141017A1 (es) 2014-08-25

Similar Documents

Publication Publication Date Title
ECSP13012859A (es) Anticuerpos del cea
CY1123550T1 (el) Διπλοειδικα egfr/c-met αντισωματα
CY1123079T1 (el) Τροποποιημενα πολυπεπτιδια γiα ικριωματα διειδικων αντισωματων
CY1121862T1 (el) Αντισωματα anti-phf-tau και χρησεις αυτων
CO7010784A2 (es) Moléculas que son anticuerpos con especificidad por ox40 humano
BR112016000903A2 (pt) anticorpos
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
BR112017004614A2 (pt) terapias de combinação com anticorpos anti-cd38
CL2017000888A1 (es) Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
DOP2016000224A (es) Tratamientos combinados con anticuerpos anti-cd38
CL2015002223A1 (es) Objetivo terapéutico y diagnostico.
EA201300819A1 (ru) Молекулы антител, которые связываются с il-17a и il-17f
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
UY35399A (es) Conjugados de fármacos con anticuerpos
CO7151527A2 (es) Anticuerpos anti-cd79 b e inmunoconjugados
CL2015002756A1 (es) Moléculas fc biespecíficas
PE20171041A1 (es) Inmunoglobulinas hetero-dimericas de redireccionamiento de celulas t cd3/cd38 y sus metodos de produccion
EA201400875A1 (ru) Антитела к cd47 и способы их применения
GT201400045A (es) Anticuerpo anti-abtcr
CO7151529A2 (es) Anticuerpos anti-cd22 e inmunoconjugados
CL2014001984A1 (es) Anticuerpos humanizados que reconozen alfa-sinucleína; metodo de produccion y sus usos.
CR20150284A (es) Terapia de combinación de anticuerpos anti-her3 y anti-her2
PL3019532T3 (pl) Ludzkie bispecyficzne cząsteczki angażujące przeciwciało egfrviii
EA201590503A1 (ru) Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями